Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell–mediated immunotherapy

Open access
Silk, Jonathan D., Hermans, Ian F., Gileadi, Uzi, Chong, Tsung Wen, Shepherd, Dawn, Salio, Mariolina, Mathew, Bini, Schmidt, Richard R., Lunt, Sarah Jane, Williams, Kaye J., Stratford, Ian J., Harris, Adrian L., Cerundolo, Vincenzo·2004·Journal of Clinical Investigation

Abstract

Activation of invariant CD1d-dependent NK T cells (iNKT cells) in vivo through administration of the glycolipid ligand alpha-galactosylceramide (alpha-GalCer) or the sphingosine-truncated alpha-GalCer analog OCH leads to CD40 signaling as well as the release of soluble molecules including type 1 and gamma interferons that contribute to DC maturation. This process enhances T cell immunity to antigens presented by the DC. The adjuvant activity is further amplified if APCs are stimulated through Toll-like receptor 4, suggesting that iNKT cell signals can amplify maturation induced by microbial stimuli. The adjuvant activity of alpha-GalCer enhances both priming and boosting of CD8(+) T cells to coadministered peptide or protein antigens, including a peptide encoding the clinically relevant, HLA-A2-restricted epitope of the human tumor antigen NY-ESO-1. Importantly, alpha-GalCer was used to induce CD8(+) T cells to antigens delivered orally, despite the fact that this route of administration is normally associated with blunted responses. Only T cell responses induced in the presence of iNKT cell stimulation, whether by the i.v. or oral route, were capable of eradicating established tumors. Together these data highlight the therapeutic potential of iNKT cell ligands in vaccination strategies, particularly "heterologous prime-boost" strategies against tumors, and provide evidence that iNKT cell stimulation may be exploited in the development of oral vaccines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci200422046

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 174

Metadata

Authors
Silk, J. D., Hermans, I. F., Gileadi, U., Chong, T. W., Shepherd, D., Salio, M., Mathew, B., Schmidt, R. R., Lunt, S. J., Williams, K. J., Stratford, I. J., Harris, A. L., & Cerundolo, V.
Venue
Journal of Clinical Investigation
Published
2004-12-15
Volume
114
Issue
12
Pages
1800-1811
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2169141824
Cited by
174
References
2
FWCI
3.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell–mediated immunotherapy. https://app.cochat.ai/papers/10.1172/jci200422046
The paper
Silk, J. D., Hermans, I. F., Gileadi, U., Chong, T. W., Shepherd, D., Salio, M., Mathew, B., Schmidt, R. R., Lunt, S. J., Williams, K. J., Stratford, I. J., Harris, A. L., & Cerundolo, V. (2004). Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell–mediated immunotherapy. Journal of Clinical Investigation. https://doi.org/10.1172/jci200422046

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.